Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study

Abstract Background Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban tre...

Cijeli opis

Bibliografski detalji

Glavni autori:	Mette Søgaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Torben Bjerregaard Larsen
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2019-03-01
Serija:	Cancer Medicine
Teme:	anticoagulants bleeding cancer rivaroxaban venous thromboembolism
Online pristup:	https://doi.org/10.1002/cam4.1997
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!